COVID-19 and financial toxicity in patients with renal cell carcinoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-10-22

AUTHORS

Michael D. Staehler, Dena J. Battle, Cristiane D. Bergerot, Sumanta Kumar Pal, David F. Penson

ABSTRACT

PurposeTo ascertain renal cell carcinoma (RCC) financial toxicity on COVID-19 during the COVID-19 crisis as patients are struggling with therapeutic and financial implications.MethodsAn online survey was conducted from March 22 to March 25, 2020. It included baseline demographic, clinicopathologic, treatment-related information, anxiety levels related to COVID-19, questions related to financial concerns about COVID-19 as well as the validated 11-item COST measure.ResultsFive-hundred-and-thirty-nine patients (39%:58% male:female) from 14 countries responded. 23% of the patients did not feel in control of their financial situation but 8% reported being very satisfied with their finances. The median COST score was 21.5 (range 1–44). Metastatic patients who have not started systemic therapy had a COST score (19.8 range 2–41) versus patients on oral systemic therapy had a COST score (23.9 range 4–44). Patients in follow-up after surgery had a median COST score at 20.8 (range 1–40). A low COST scores correlated (p < 0.001) were female gender (r = 0.108), younger age (r = 0.210), urban living situation (r = 0.68), a lower educational level (r = 0.155), lower income (r = 0.165), higher anxiety about acquiring COVID-19 (r = 0.198), having metastatic disease (r = 0.073) and a higher distress score about cancer progression (r = 0.224).ConclusionOur data highlight severe financial impact of COVID-19. Acknowledging financial hardship and thorough counseling of cancer patients should be part of the conversation during the pandemic. Treatment and surveillance of RCC patients might have to be adjusted to contemplate financial and medical needs. More... »

PAGES

2559-2565

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00345-020-03476-6

DOI

http://dx.doi.org/10.1007/s00345-020-03476-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1131947459

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33090258


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "COVID-19", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost of Illness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Financial Stress", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Psycho-Oncology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "SARS-CoV-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Urology, Ludwig-Maximilians University, University of Munich, Marchioninistr. 15, 81377, Munich, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Department of Urology, Ludwig-Maximilians University, University of Munich, Marchioninistr. 15, 81377, Munich, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Staehler", 
        "givenName": "Michael D.", 
        "id": "sg:person.01137740510.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137740510.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kidney Cancer Research Alliance (KCCure), Alexandria, VA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Kidney Cancer Research Alliance (KCCure), Alexandria, VA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Battle", 
        "givenName": "Dena J.", 
        "id": "sg:person.012255146260.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012255146260.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bergerot", 
        "givenName": "Cristiane D.", 
        "id": "sg:person.01073214554.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073214554.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pal", 
        "givenName": "Sumanta Kumar", 
        "id": "sg:person.01162002222.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162002222.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.412807.8", 
          "name": [
            "Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Penson", 
        "givenName": "David F.", 
        "id": "sg:person.013740101457.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013740101457.47"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2020-10-22", 
    "datePublishedReg": "2020-10-22", 
    "description": "PurposeTo ascertain renal cell carcinoma (RCC) financial toxicity on COVID-19 during the COVID-19 crisis as patients are struggling with therapeutic and financial implications.MethodsAn online survey was conducted from March 22 to March 25, 2020. It included baseline demographic, clinicopathologic, treatment-related information, anxiety levels related to COVID-19, questions related to financial concerns about COVID-19 as well as the validated 11-item COST measure.ResultsFive-hundred-and-thirty-nine patients (39%:58% male:female) from 14 countries responded. 23% of the patients did not feel in control of their financial situation but 8% reported being very satisfied with their finances. The median COST score was 21.5 (range 1\u201344). Metastatic patients who have not started systemic therapy had a COST score (19.8 range 2\u201341) versus patients on oral systemic therapy had a COST score (23.9 range 4\u201344). Patients in follow-up after surgery had a median COST score at 20.8 (range 1\u201340). A low COST scores correlated (p\u2009<\u20090.001) were female gender (r\u2009=\u20090.108), younger age (r\u2009=\u20090.210), urban living situation (r\u2009=\u20090.68), a lower educational level (r\u2009=\u20090.155), lower income (r\u2009=\u20090.165), higher anxiety about acquiring COVID-19 (r\u2009=\u20090.198), having metastatic disease (r\u2009=\u20090.073) and a higher distress score about cancer progression (r\u2009=\u20090.224).ConclusionOur data highlight severe financial impact of COVID-19. Acknowledging financial hardship and thorough counseling of cancer patients should be part of the conversation during the pandemic. Treatment and surveillance of RCC patients might have to be adjusted to contemplate financial and medical needs.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00345-020-03476-6", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1094127", 
        "issn": [
          "0724-4983", 
          "1433-8726"
        ], 
        "name": "World Journal of Urology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "39"
      }
    ], 
    "keywords": [
      "systemic therapy", 
      "COVID-19", 
      "median COST score", 
      "financial toxicity", 
      "oral systemic therapy", 
      "treatment-related information", 
      "renal cell carcinoma", 
      "COST score", 
      "higher distress scores", 
      "MethodsAn online survey", 
      "baseline demographics", 
      "ResultsFive hundred", 
      "metastatic patients", 
      "metastatic disease", 
      "thorough counseling", 
      "RCC patients", 
      "cell carcinoma", 
      "cancer patients", 
      "female gender", 
      "patients", 
      "younger age", 
      "distress scores", 
      "medical need", 
      "cancer progression", 
      "anxiety levels", 
      "scores", 
      "therapy", 
      "living situations", 
      "educational level", 
      "high anxiety", 
      "low income", 
      "lower COST scores", 
      "financial concerns", 
      "financial hardship", 
      "toxicity", 
      "financial implications", 
      "online survey", 
      "financial impact", 
      "surgery", 
      "carcinoma", 
      "PurposeTo", 
      "disease", 
      "severe financial impact", 
      "progression", 
      "demographics", 
      "age", 
      "counseling", 
      "levels", 
      "treatment", 
      "surveillance", 
      "anxiety", 
      "gender", 
      "pandemic", 
      "COVID-19 crisis", 
      "control", 
      "measures", 
      "survey", 
      "need", 
      "concern", 
      "financial situation", 
      "countries", 
      "impact", 
      "hardship", 
      "implications", 
      "situation", 
      "income", 
      "cost measures", 
      "information", 
      "part", 
      "questions", 
      "crisis", 
      "conversation", 
      "finance"
    ], 
    "name": "COVID-19 and financial toxicity in patients with renal cell carcinoma", 
    "pagination": "2559-2565", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1131947459"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00345-020-03476-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33090258"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00345-020-03476-6", 
      "https://app.dimensions.ai/details/publication/pub.1131947459"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_851.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00345-020-03476-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00345-020-03476-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00345-020-03476-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00345-020-03476-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00345-020-03476-6'


 

This table displays all metadata directly associated to this object as RDF triples.

235 TRIPLES      20 PREDICATES      114 URIs      106 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00345-020-03476-6 schema:about N00e16f28dbee4b9f825d4c6baa04244f
2 N444fbd0c80c840d8baec04ebac3a4542
3 N5479eaf46ab54888b4fafba0afc147d5
4 N63731123f97449a3991f60118d79f378
5 N6e9170cca6c648fabc8252364db21e7e
6 N6ea279fa9178403985323db9f1e18e1b
7 N89e880c5e26a4716aea21c7c4655e0cc
8 Nab995dd0a98a4292b255056c077b6a46
9 Nbb601bf25cc648359537af1a19c893f5
10 Ncbd4fb55baef487ba3549899d82f853c
11 Nd8d57b43897142f994bc0d2c62daceea
12 Ndd497df5a9d0474ca60255f1aa788aff
13 Ne2949cafacfe4384af80c23f36f78902
14 Ne47cba2e62814108b247c3df9b255599
15 Ne55d4ed7de6846458928a36c98e6daf1
16 Nf5902043973644c7a7988fad46a6f91a
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N41018dc4a9524232834885cab3e35c36
20 schema:datePublished 2020-10-22
21 schema:datePublishedReg 2020-10-22
22 schema:description PurposeTo ascertain renal cell carcinoma (RCC) financial toxicity on COVID-19 during the COVID-19 crisis as patients are struggling with therapeutic and financial implications.MethodsAn online survey was conducted from March 22 to March 25, 2020. It included baseline demographic, clinicopathologic, treatment-related information, anxiety levels related to COVID-19, questions related to financial concerns about COVID-19 as well as the validated 11-item COST measure.ResultsFive-hundred-and-thirty-nine patients (39%:58% male:female) from 14 countries responded. 23% of the patients did not feel in control of their financial situation but 8% reported being very satisfied with their finances. The median COST score was 21.5 (range 1–44). Metastatic patients who have not started systemic therapy had a COST score (19.8 range 2–41) versus patients on oral systemic therapy had a COST score (23.9 range 4–44). Patients in follow-up after surgery had a median COST score at 20.8 (range 1–40). A low COST scores correlated (p < 0.001) were female gender (r = 0.108), younger age (r = 0.210), urban living situation (r = 0.68), a lower educational level (r = 0.155), lower income (r = 0.165), higher anxiety about acquiring COVID-19 (r = 0.198), having metastatic disease (r = 0.073) and a higher distress score about cancer progression (r = 0.224).ConclusionOur data highlight severe financial impact of COVID-19. Acknowledging financial hardship and thorough counseling of cancer patients should be part of the conversation during the pandemic. Treatment and surveillance of RCC patients might have to be adjusted to contemplate financial and medical needs.
23 schema:genre article
24 schema:isAccessibleForFree true
25 schema:isPartOf N68ca2b5d51144893a2b80f8f71dfb9fa
26 N9571956c27d04b1999b28d1493373f22
27 sg:journal.1094127
28 schema:keywords COST score
29 COVID-19
30 COVID-19 crisis
31 MethodsAn online survey
32 PurposeTo
33 RCC patients
34 ResultsFive hundred
35 age
36 anxiety
37 anxiety levels
38 baseline demographics
39 cancer patients
40 cancer progression
41 carcinoma
42 cell carcinoma
43 concern
44 control
45 conversation
46 cost measures
47 counseling
48 countries
49 crisis
50 demographics
51 disease
52 distress scores
53 educational level
54 female gender
55 finance
56 financial concerns
57 financial hardship
58 financial impact
59 financial implications
60 financial situation
61 financial toxicity
62 gender
63 hardship
64 high anxiety
65 higher distress scores
66 impact
67 implications
68 income
69 information
70 levels
71 living situations
72 low income
73 lower COST scores
74 measures
75 median COST score
76 medical need
77 metastatic disease
78 metastatic patients
79 need
80 online survey
81 oral systemic therapy
82 pandemic
83 part
84 patients
85 progression
86 questions
87 renal cell carcinoma
88 scores
89 severe financial impact
90 situation
91 surgery
92 surveillance
93 survey
94 systemic therapy
95 therapy
96 thorough counseling
97 toxicity
98 treatment
99 treatment-related information
100 younger age
101 schema:name COVID-19 and financial toxicity in patients with renal cell carcinoma
102 schema:pagination 2559-2565
103 schema:productId N5c5cbaba4d104941ba95ec4fb858e9d9
104 N9b620ebb064944eb9702ad4349c03200
105 Neb5e100581cd41218d474ed64d0ad492
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1131947459
107 https://doi.org/10.1007/s00345-020-03476-6
108 schema:sdDatePublished 2022-10-01T06:47
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher Ne409650789aa4dc783b02ebab567a880
111 schema:url https://doi.org/10.1007/s00345-020-03476-6
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N00e16f28dbee4b9f825d4c6baa04244f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Psycho-Oncology
117 rdf:type schema:DefinedTerm
118 N41018dc4a9524232834885cab3e35c36 rdf:first sg:person.01137740510.53
119 rdf:rest Nb11654a9cd214ea4bd34005d021c9d0f
120 N444fbd0c80c840d8baec04ebac3a4542 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Kidney Neoplasms
122 rdf:type schema:DefinedTerm
123 N5479eaf46ab54888b4fafba0afc147d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Antineoplastic Agents
125 rdf:type schema:DefinedTerm
126 N5c5cbaba4d104941ba95ec4fb858e9d9 schema:name dimensions_id
127 schema:value pub.1131947459
128 rdf:type schema:PropertyValue
129 N63731123f97449a3991f60118d79f378 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Female
131 rdf:type schema:DefinedTerm
132 N68ca2b5d51144893a2b80f8f71dfb9fa schema:issueNumber 7
133 rdf:type schema:PublicationIssue
134 N6e9170cca6c648fabc8252364db21e7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Neoplasm Staging
136 rdf:type schema:DefinedTerm
137 N6ea279fa9178403985323db9f1e18e1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Male
139 rdf:type schema:DefinedTerm
140 N89e880c5e26a4716aea21c7c4655e0cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name SARS-CoV-2
142 rdf:type schema:DefinedTerm
143 N9571956c27d04b1999b28d1493373f22 schema:volumeNumber 39
144 rdf:type schema:PublicationVolume
145 N9b620ebb064944eb9702ad4349c03200 schema:name pubmed_id
146 schema:value 33090258
147 rdf:type schema:PropertyValue
148 Na2089c722c5f47ea952788ea112d60da rdf:first sg:person.013740101457.47
149 rdf:rest rdf:nil
150 Nab995dd0a98a4292b255056c077b6a46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Carcinoma, Renal Cell
152 rdf:type schema:DefinedTerm
153 Nb11654a9cd214ea4bd34005d021c9d0f rdf:first sg:person.012255146260.77
154 rdf:rest Nf0b6cc2e56264dbaacb87a51e3b82503
155 Nbb601bf25cc648359537af1a19c893f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Surveys and Questionnaires
157 rdf:type schema:DefinedTerm
158 Ncbbaa6fd3e3b441d8c301155ffa621b9 rdf:first sg:person.01162002222.57
159 rdf:rest Na2089c722c5f47ea952788ea112d60da
160 Ncbd4fb55baef487ba3549899d82f853c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Middle Aged
162 rdf:type schema:DefinedTerm
163 Nd8d57b43897142f994bc0d2c62daceea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Quality of Life
165 rdf:type schema:DefinedTerm
166 Ndd497df5a9d0474ca60255f1aa788aff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name United States
168 rdf:type schema:DefinedTerm
169 Ne2949cafacfe4384af80c23f36f78902 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Financial Stress
171 rdf:type schema:DefinedTerm
172 Ne409650789aa4dc783b02ebab567a880 schema:name Springer Nature - SN SciGraph project
173 rdf:type schema:Organization
174 Ne47cba2e62814108b247c3df9b255599 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name COVID-19
176 rdf:type schema:DefinedTerm
177 Ne55d4ed7de6846458928a36c98e6daf1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Humans
179 rdf:type schema:DefinedTerm
180 Neb5e100581cd41218d474ed64d0ad492 schema:name doi
181 schema:value 10.1007/s00345-020-03476-6
182 rdf:type schema:PropertyValue
183 Nf0b6cc2e56264dbaacb87a51e3b82503 rdf:first sg:person.01073214554.52
184 rdf:rest Ncbbaa6fd3e3b441d8c301155ffa621b9
185 Nf5902043973644c7a7988fad46a6f91a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Cost of Illness
187 rdf:type schema:DefinedTerm
188 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
189 schema:name Medical and Health Sciences
190 rdf:type schema:DefinedTerm
191 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
192 schema:name Oncology and Carcinogenesis
193 rdf:type schema:DefinedTerm
194 sg:journal.1094127 schema:issn 0724-4983
195 1433-8726
196 schema:name World Journal of Urology
197 schema:publisher Springer Nature
198 rdf:type schema:Periodical
199 sg:person.01073214554.52 schema:affiliation grid-institutes:grid.410425.6
200 schema:familyName Bergerot
201 schema:givenName Cristiane D.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073214554.52
203 rdf:type schema:Person
204 sg:person.01137740510.53 schema:affiliation grid-institutes:grid.5252.0
205 schema:familyName Staehler
206 schema:givenName Michael D.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137740510.53
208 rdf:type schema:Person
209 sg:person.01162002222.57 schema:affiliation grid-institutes:grid.410425.6
210 schema:familyName Pal
211 schema:givenName Sumanta Kumar
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162002222.57
213 rdf:type schema:Person
214 sg:person.012255146260.77 schema:affiliation grid-institutes:None
215 schema:familyName Battle
216 schema:givenName Dena J.
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012255146260.77
218 rdf:type schema:Person
219 sg:person.013740101457.47 schema:affiliation grid-institutes:grid.412807.8
220 schema:familyName Penson
221 schema:givenName David F.
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013740101457.47
223 rdf:type schema:Person
224 grid-institutes:None schema:alternateName Kidney Cancer Research Alliance (KCCure), Alexandria, VA, USA
225 schema:name Kidney Cancer Research Alliance (KCCure), Alexandria, VA, USA
226 rdf:type schema:Organization
227 grid-institutes:grid.410425.6 schema:alternateName Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
228 schema:name Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
229 rdf:type schema:Organization
230 grid-institutes:grid.412807.8 schema:alternateName Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA
231 schema:name Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA
232 rdf:type schema:Organization
233 grid-institutes:grid.5252.0 schema:alternateName Department of Urology, Ludwig-Maximilians University, University of Munich, Marchioninistr. 15, 81377, Munich, Germany
234 schema:name Department of Urology, Ludwig-Maximilians University, University of Munich, Marchioninistr. 15, 81377, Munich, Germany
235 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...